Nelson, N, Lombardo, J, Matlack, L, et al. Chronoradiobiology of breast cancer: The time is now to link circadian rhythm and radiation biology. Int J Mol Sci, 23, 2022, 1331.
Hanna, TP, King, WD, Thibodeau, S, et al. Mortality due to cancer treatment delay: Systematic review and meta-analysis. BMJ, 371, 2020, m4087.
Morrill, KE, Robles-, R, Lopez-, M, et al. Factors associated with cancer treatment delay: A protocol for a systematic review and meta-analysis. BMJ Open 12 (2022), 1–6.
Riera, R, Bagattini, ÂM, Pacheco, RL, Pachito, DV, Roitberg, F, Ilbawi, A., Delays and disruptions in cancer health care due to COVID-19 pandemic: Systematic review. JCO Glob Oncol, 2021, 311–323.
Gensheimer, MF, Zeng, J, Carlson, J, et al. Influence of planning time and treatment complexity on radiation therapy errors. Pract Radiat Oncol 6 (2016), 187–193.
Distefano, G, Garikipati, S, Grimes, H, Hatton, M., Current status of stereotactic ablative body radiotherapy in the UK: Six years of progress. BJR Open, 1, 2019, 20190022.
Palma, DA, Olson, R, Harrow, S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial. BMC Cancer 19 (2019), 1–15.
Raju, SC, Peters, GW, Decker, RH, Park, HS., Clinical outcomes and safety profile in the treatment of synchronous nonmetastatic lung tumors with stereotactic body radiation therapy. Pract Radiat Oncol 12 (2022), e110–e116.
Seymour, ZA, Fogh, SE, Westcott, SK, et al. Interval from imaging to treatment delivery in the radiation surgery age: How long is too long?. Int J Radiat Oncol Biol Phys 93 (2015), 126–132.
Salkeld, AL, Hau, EKC, Nahar, N, Sykes, JR, Wang, W, Thwaites, DI., Changes in brain metastasis during radiosurgical planning. Int J Radiat Oncol Biol Phys 102 (2018), 727–733.
Videtic, GM, Paulus, R, Singh, AK, et al. Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys 103 (2019), 1077–1084.
Palma, DA, Olson, R, Harrow, S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38 (2020), 2830–2838.
Olson, R, Mathews, L, Liu, M, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): Study protocol for a randomized phase III trial. BMC Cancer 20 (2020), 1–12.
Das, IJ, Dawes, SL, Dominello, MM, et al. Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: An ASTRO safety white paper update. Pract Radiat Oncol 12 (2022), e253–e268.
Berkovic, P, Gulyban, A, Defraene, G, et al. Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases. BMC Cancer 20 (2020), 1–9.
Janvary, ZL, Jansen, N, Baart, V, et al. Clinical outcomes of 130 patients with primary and secondary lung tumors treated with CyberKnife robotic stereotactic body radiotherapy. Radiol Oncol 51 (2017), 178–186.
Lim-Reinders, S, Keller, BM, Al-Ward, S, Sahgal, A, Kim, A, Online adaptive radiation therapy. Int J Radiat Oncol Biol Phys 99 (2017), 994–1003.
Alamilla-Presuel, JC, Burgos-Molina, AM, González-Vidal, A, Sendra-Portero, F, Ruiz-Gómez, MJ., Factors and molecular mechanisms of radiation resistance in cancer cells. Int J Radiat Biol 98 (2022), 1301–1315.
Chen, HJ, Liang, JA, Chen, CY, Yu, YH, Chien, CR., What if a tumor is significantly enlarged just before stereotactic body radiation therapy? A case report and review of the literature. Thorac Cancer 8 (2017), 118–120.
Bentzen, SM, Thames, HD., Tumor volume and local control probability: Clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys 36 (1996), 247–251.
Virbel, G, Le, Fèvre C, Noël, G, Antoni, D, Stereotactic body radiotherapy for patients with lung oligometastatic disease: A five-year review. Cancers (Basel), 13, 2021, 3623.
Murai, T, Shibamoto, Y, Baba, F, et al. Progression of non-small-cell lung cancer during the interval before stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 82 (2012), 463–467.
Guckenberger, M, Klement, RJ, Allgäuer, M, et al. Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol 118 (2016), 485–491.
Diamant, A, Chatterjee, A, Faria, S, et al. Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)?. Radiother Oncol 128 (2018), 513–519.
Davey, A, van Herk, M, Faivre-Finn, C, McWilliam, A., radial data mining to identify density–dose interactions that predict distant failure following SABR. Front Oncol 12 (2022), 1–13.
